Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 3/20 | 0.36 |
| ▸ | PRKCA | P17252 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346061 | 0.88 | GRIK1 (0.30) | — | |
| SCHEMBL4344789 | 0.85 | GRIK1 (0.31) | — | |
| SCHEMBL2365209 | 0.75 | ALDH1A1 (0.36) | POLB | |
| SCHEMBL12971533 | 0.75 | PTGES (0.38) | ALOX5PTGESAPEX1 | |
| SCHEMBL322607 | 0.73 | GRIK1 (0.51) | ALOX5PTGESCYP1A2APEX1MEN1 | |
| SCHEMBL692340 | 0.73 | GRIK1 (0.51) | ALOX5PTGESCYP1A2APEX1MEN1 | |
| SCHEMBL7971787 | 0.71 | CA1 (0.31) | — | |
| SCHEMBL1957701 | 0.71 | CA1 (0.38) | KMT2A | |
| Phosphoric Acid SCHEMBL17507878 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL17845981 | 0.69 | CYP1A2 (0.44) | CYP1A2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| EP-1718347-B1 | BIOCOMPATIBLE COATING, METHOD, AND USE OF MEDICAL SURFACES | HEMOTEQ AG (DE) | 2017-03-08 | — | — | EP | claimed |
| EP-1881853-B1 | ALL-OVER COATING OF VESSEL STENTS | HEMOTEQ AG (DE) | 2016-09-28 | — | — | EP | claimed |
| EP-2114481-B1 | BIODEGRADABLE VASCULAR SUPPORT | HEMOTEQ AG (DE) | 2015-09-30 | — | — | EP | claimed |
| EP-2744532-B1 | RESORBABLE STENTS CONTAINING A MAGNESIUM ALLOY | MEKO LASERSTRAHL MATERIALBEARBEITUNGEN E K (DE) | 2015-09-16 | — | — | EP | claimed |
| US-8916227-B2 | Coating of the entire surface of endoprostheses | HEMOTEQ AG (DE) | 2014-12-23 | — | — | US | claimed |
| US-8679520-B2 | Coating of stents for preventing restenosis | HEMOTEQ AG (DE) | 2014-03-25 | — | — | US | claimed |
| US-20130345296-A1 | Compositions Comprising a Taxane for Coating Medical Devices | AVIDAL VASCULAR GMBH (DE) | 2013-12-26 | — | — | US | claimed |
| EP-2632450-A1 | COMPOSITIONS COMPRISING A TAXANE FOR COATING MEDICAL DEVICES | Avidal Vascular GmbH (DE) | 2013-09-04 | — | — | EP | claimed |
| WO-2012028311-A1 | COMPOSITIONS COMPRISING A TAXANE FOR COATING MEDICAL DEVICES | AVIDAL VASCULAR GMBH (DE) | 2012-03-08 | — | — | WO | claimed |
| EP-2106820-A1 | Expansible biocompatible coats comprising a biologically active substance | Heilmann, Torsten (DE) | 2009-10-07 | — | — | EP | claimed |
| EP-1435877-B1 | COATING OF STENTS FOR PREVENTING RESTENOSIS | HEMOTEQ AG (DE) | 2009-04-15 | — | — | EP | claimed |
| US-20080199506-A1 | Lattice or mesh-like structure; covering with thin film over interstices and supports with multilayer polymer | HEMOTEQ AG (DE) | 2008-08-21 | — | — | US | claimed |
| WO-2008087488-A2 | EXPANDABLE MEDICAL DEVICE FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | PERELSON OPHIR (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1913962-A1 | Expandable medical device for the treatment and prevention of cardiovascular diseases | Perelson, Ophir (US) | 2008-04-23 | — | — | EP | claimed |
| US-20080038307-A1 | Biocompatible Coating, Method, and Use of Medical Surfaces | HEMOTEQ AG (DE) | 2008-02-14 | — | — | US | claimed |
| EP-1501565-B1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | HEMOTEQ GMBH (DE) | 2006-11-02 | — | — | EP | claimed |
| US-20050176678-A1 | Oligosaccharide or polysaccharide which contain sugar segments; antiproliferative agents; antiinflammatory agents; anticoagulants | HEMOTEQ AG (DE) | 2005-08-11 | — | — | US | claimed |
| US-20050060028-A1 | Blood biocompatible layer and adjacent layer containing antiproliferative, antiinflammatory and/or antithrombotic active agent covalently and/or adhesively bound | HEMOTEQ AG (DE) | 2005-03-17 | — | — | US | claimed |
| US-20040234575-A1 | oligosaccharides, polysaccharides containing sugar segments; stents | HEMOTEQ AG (DE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038307-A1 | Biocompatible Coating, Method, and Use of Medical Surfaces | ALOX5, CD68, CD14 | ALOX5 1/4885PTGES 67/4885CYP1A2 997/4885 |
| US-20050176678-A1 | Oligosaccharide or polysaccharide which contain sugar segments; antiproliferative agents; antiinflammatory agents; anticoagulants | FUT5, CSGALNACT1, FUT6 | ALOX5 379/4885PTGES 953/4885CYP1A2 4135/4885 |
| US-20130345296-A1 | Compositions Comprising a Taxane for Coating Medical Devices | ALDH1A1, ALDH16A1, ALDH2 | ALOX5 1394/4885PTGES 1913/4885CYP1A2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.